Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.

On July 27, the Indonesia-China Healthcare and Biotechnology Investment Forum, co-sponsored by the Embassy of the Republic of Indonesia in China and the China Committee of the Indonesian Chamber of Commerce and Industry, was held in Chengdu.

Siemens Healthineers AG today announces its results for the third quarter, ending June 30, of fiscal year 2023.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2023.

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration".

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Respiratory Viral Panel (RVP) for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 2, 2023.

According to the forecast of GHICapital, the market size of China's dPCR industry will still maintain a high growth rate from 2020 to 2024, and the market size will grow from 2.133 billion yuan to 7.011 billion yuan, at a CAGR of 34.65%.

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia symptoms arise.

Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company, announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca, a global biopharmaceutical company.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ( ¡°Mindray¡±) has agreed to acquire 75% equity interest in DiaSys Diagnostic Systems GmbH (¡°DiaSys¡±) from Gorka Holding GmbH, through Mindray Medical Netherlands B.V. (¡°Mindray Netherlands¡±), a wholly-owned subsidiary of Mindray¡¯s wholly-owned subsidiary MR Global (HK) Limited, for an all-cash preliminary purchase price of approx. €115 million.

Recently, according to the internal announcement of Abbott Healthcare, the general manager of Abbott Electrophysiology China will be adjusted, and Liu Bei (Laura), the former senior director of Valve Therapeutics Business Unit of Edwards China, will take up this position from July 20th.

Meridian Bioscience said on Tuesday that it has received US Food and Drug Administration clearance for its Premier HpSA Flex assay for the diagnosis of Helicobacter pylori in both preserved and unpreserved stools.

Laboratory Corporation of America reported on Thursday that its second quarter revenues grew 4 percent year over year, including a 13 percent gain in its base business, which excludes COVID-19 testing revenues.

Recently, Wondfo Bio and Merck, a leading global technology company, held a globalization cooperation seminar and unanimously decided to deepen the cooperation on the basis of the pilot cooperation in the previous period, expanding the project coverage area and the population, and joining hands to enhance the accessibility of the diagnosis and treatment of thyroid diseases at the grassroots level in the world.

DiaSorin said on Thursday that its second quarter revenues fell around 12 percent year over year on a constant currency basis, as it experienced an expected continued sharp decline in COVID-19 testing, partially offset by improvements in other immunodiagnostics sales.

Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER)

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe Fund as a limited partner, with a subscription amount of RMB 100 million.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.